Myeloma: risk stratified treatment and monitoring
Tracks
-
| Sunday, April 19, 2026 |
| 4:20 PM - 5:50 PM |
| Hall 1A, Upper Level |
Details
This session is developed in collaboration with UKMS/UKMRA.
Long term projections from quadruplet therapy trials suggest curative potential from myeloma regimens for a proportion of low risk patients. However, high risk myeloma remains a challenging subgroup to treat (30% of newly diagnosed myeloma patients).
In this session we will cover the new IMS 2025 classification, results from the high risk arm of the UK RADAR trial, alternative treatment approaches from the US and monitoring practices for high risk patients to prevent aggressive relapse.
Speaker
Dr. Rachel Hall
Consultant Haematologist
University Hospitals Dorset
Welcome and Introduction of Speakers
4:20 PM - 4:30 PM
Prof. Karthik Ramasamy
Professor Of Haematology
Oxford University Hospitals NHS Foundation Trust
Management of high risk myeloma - A UK perspective
4:30 PM - 4:45 PM
Prof. Luciano Costa
Professor Of Medicine
University of Alabama at Birmingham
Management of high risk myeloma - A US perspective
4:45 PM - 5:15 PM
Dr. Ceri Bygrave
Consultant Haematologist
UKMS
The use of diagnostic and monitoring tools in the management of high risk myeloma
5:15 PM - 5:30 PM
Dr Rakesh Popat
Consultant Haematologist;
University College London Hospitals
Relevance to UK clinical practice, Q+A and close
5:30 PM - 5:50 PM
Dr. Rachel Hall
Consultant Haematologist
University Hospitals Dorset
Session Chair
